Lara A Dunn
Overview
Explore the profile of Lara A Dunn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Febres-Aldana C, Elsayad M, Saliba M, Bhanot U, Ntiamoah P, Takeyama A, et al.
Mod Pathol
. 2024 Nov;
38(3):100674.
PMID: 39613231
The diagnosis and treatment of sinonasal small round epithelial/neuroepithelial malignancies depend on the expression of conventional neuroendocrine markers (NEMs), such as synaptophysin, chromogranin A, INSM1, and CD56/NCAM1. However, these tumors...
2.
Desilets A, Vos J, Katabi N, Kuo F, Nadeem Z, Linxweiler M, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5281-5292.
PMID: 39352719
Purpose: There is a significant need for effective therapies to treat recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC). This study evaluated the multitargeted VEGFR tyrosine kinase inhibitor (TKI) regorafenib in patients...
3.
Hughes B, Guminski A, Bowyer S, Migden M, Schmults C, Khushalani N, et al.
J Am Acad Dermatol
. 2024 Sep;
92(1):68-77.
PMID: 39245360
Background: In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC). Objectives: To report...
4.
Desilets A, Pfister D, Stein S, Wong W, Sherman E, Fetten J, et al.
Oral Oncol
. 2024 May;
154:106861.
PMID: 38795600
Objectives: Epidermal growth factor receptor (EGFR) inhibition with cetuximab is a standard treatment for head and neck squamous cell carcinoma (HNSCC). Activation of the receptor tyrosine kinases AXL, MET and...
5.
Barker C, Dufault S, Arron S, Ho A, Algazi A, Dunn L, et al.
J Clin Oncol
. 2024 Apr;
42(19):2327-2335.
PMID: 38630954
Purpose: Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI)...
6.
Lee N, Sherman E, Schoder H, Wray R, Boyle J, Singh B, et al.
J Clin Oncol
. 2024 Jan;
42(8):940-950.
PMID: 38241600
Purpose: Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)-related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could identify...
7.
Tam K, Dunn L, Cohen M
Curr Opin Otolaryngol Head Neck Surg
. 2023 Dec;
32(1):14-19.
PMID: 38116847
Purpose Of Review: The purpose of this review is to summarize current evidence regarding the use of induction chemotherapy for a variety of histopathologies of sinonasal malignancy (SNMs) and to...
8.
Vos J, Burman B, Jain S, Fitzgerald C, Sherman E, Dunn L, et al.
Nat Med
. 2023 Aug;
29(12):3077-3089.
PMID: 37620627
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) and ipilimumab (ipi, anti-CTLA-4) in 64 patients...
9.
Lee A, Woods R, Mahfouz A, Kitpanit S, Cartano O, Mohamed N, et al.
JAMA Netw Open
. 2023 Jan;
6(1):e2250607.
PMID: 36689229
Importance: Use of proton therapy reirradiation (PT-ReRT) for head and neck cancer is increasing; however, reports are heterogenous and outcomes can be difficult to interpret. Objective: To evaluate outcomes and...
10.
Kang J, Yu Y, Chen L, Zakeri K, Gelblum D, McBride S, et al.
CA Cancer J Clin
. 2022 Oct;
73(2):164-197.
PMID: 36305841
The most common cancer caused by human papillomavirus (HPV) infection in the United States is oropharyngeal cancer (OPC), and its incidence has been rising since the turn of the century....